These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease. Bykowska K, Letowska M, Sabliński J, Binder BR, Kopeć M, Lopaciuk S. Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599 [Abstract] [Full Text] [Related]
3. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease. Wieczorek I, Ludlam CA, MacGregor IR. Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304 [Abstract] [Full Text] [Related]
6. [Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men]. Rość D, Drewniak W, Kinasz-Rózycka I, Kulwas A, Michalski A. Pol Merkur Lekarski; 2003 Dec; 15(90):518-20. PubMed ID: 15058251 [Abstract] [Full Text] [Related]
7. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Erem C. Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444 [Abstract] [Full Text] [Related]
8. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A, Ruusuvaara L. Thromb Haemost; 1988 Dec 22; 60(3):361-4. PubMed ID: 3149043 [Abstract] [Full Text] [Related]
10. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ. Thromb Haemost; 2007 Jun 22; 97(6):922-30. PubMed ID: 17549293 [Abstract] [Full Text] [Related]
12. Sympathoadrenal activation and muscarinic receptor stimulation induce acute release of tissue-type plasminogen activator but not von Willebrand factor across the human forearm. Jern C, Selin L, Tengborn L, Jern S. Thromb Haemost; 1997 Aug 22; 78(2):887-91. PubMed ID: 9268190 [Abstract] [Full Text] [Related]
13. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A, Berneman Z, Schroyens W, Michiels JJ. Acta Haematol; 2009 Aug 22; 121(2-3):128-38. PubMed ID: 19506359 [Abstract] [Full Text] [Related]
18. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z. Semin Thromb Hemost; 2002 Apr 22; 28(2):111-32. PubMed ID: 11992235 [Abstract] [Full Text] [Related]
19. Defective interaction between von Willebrand factor and platelet glycoprotein Ib--a familial study of peripheral arterial occlusive disease. Kauhanen P, Beer JH, Lassila R. Thromb Haemost; 1997 May 22; 77(5):849-55. PubMed ID: 9184391 [Abstract] [Full Text] [Related]